The leading source for credible citizen reporting

Report Your News
Take the tour...

This event is older than two months and is no longer active. Some links older than two months could be broken.

Report Your News

Click here to post a new related report

Firms pitch new drugs for diabetes

Ada : OK : USA | 6 months ago  
Views: 8
Major pharmaceutical companies are fighting harder over the millions of patients with diabetes, a lucrative market because the pool of customers is growing with the obesity epidemic -- and they will need daily drugs for life. As the American Diabetes Association conference opened Friday, companies...
  • Print
  • Share:
  • Share
  • Digg
  • Reddit
  • Facebook
  • Stumbleupon

Related Allvoices Contributions

News Stories
 
  • News Source: Androscoggin News | 6 months ago
    New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria(R) (albiglutide) significantly reduced blood glucose levels and provided...
  • News Source: Androscoggin News | 6 months ago
    Amylin Pharmaceuticals, Inc...These findings were presented at the 69th Annual Scientific Sessions of the American Diabetes Association ( ADA ) in New Orleans . A New Drug Application (NDA) for exenatide once weekly was recently submitted to the U.S.
  • News Source: Androscoggin News | 6 months ago
    exenatide) injection was not increased compared to patients initiating other antidiabetic therapies...In keeping with the companies' focus on patient safety, Amylin and Lilly continue to pursue a drug safety program that includes thorough...
  • News Source: The Courier-Journal | 6 months ago
    Major pharmaceutical companies are fighting harder over the millions of patients with diabetes, a lucrative market because the pool of customers is growing with the obesity epidemic -- and they will need daily drugs for life. As the American...
  • News Source: The Noblesville Ledger | 6 months ago
    Eli Lilly and Co.'s experimental long-acting version of Byetta lowered blood sugar more than Takeda Pharmaceutical's Actos or Merck's Januvia, and allowed patients to lose more weight, a study showed. Sixty-six percent of diabetics taking Byetta had...
  • News Source: Androscoggin News | 6 months ago
    Patients with type 2 diabetes over the age of 65 years may achieve better hemoglobin A 1c (HbA 1c ) lowering with insulin glargine treatment added to oral hypoglycemic agents than with the combination of NPH insulin and oral agents, according to...
Most Popular Reports

Related Allvoices Reports

Contributions

Help and Accounts


Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc 2008-2009. All rights reserved.